Bibliography
- Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):S14-21
- Swislocki AL, Siegel D, Jialal I. Pharmacotherapy for the metabolic syndrome. Curr Vasc Pharmacol 2012;10:187-205
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death. N Engl J Med 2007;356:2457-71
- Soskić SS, Dobutović BD, Sudar EM, et al. Peroxisome proliferator-activated receptors and atherosclerosis. Angiology 2011;62:523-34
- Avogaro A, Federici M, Betteridge J, et al. Which is the eligible patient to be treated with pioglitazone? The expert view. J Endocrinol Invest 2011;34:781-7
- Khan S, Khan S, Imran M, et al. Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus - targeting thrombogenesis. Expert Opin Ther Targets 2013;17(6):627-39
- Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008;9:1087-108
- Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type-2 diabetes. Expert Opin Pharmacother 2008;9:343-9
- Rizzo M, Christ ER, Rini GB, et al. The differential effects of thiazolidindiones on atherogenic dyslipidemia in type-2 diabetes: what is the clinical significance? Expert Opin Pharmacother 2008;9:2295-303
- Rizzo M, Vekic J, Koulouris S, et al. Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type-2 diabetes. Angiology 2010;61:584-90
- Rizzo M, Berneis K. Who needs to care about small, dense low density lipoproteins? Int J Clin Pract 2007;61:1949-56
- Mikhailidis DP, Elisaf MS, Rizzo M, et al. “European Panel on Low Density Lipoprotein (LDL) Subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533-71
- Mikhailidis DP, Elisaf MS, Rizzo M, et al. “European Panel on Low Density Lipoprotein (LDL) Subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011;9:531-2
- Caisse nationale de l’assurance maladie (CNAMTS). Risk of blabber cancer in people with diabetes treated with pioglitazone in France: a group study on SNIIRAM and PMSI data. Final report 7/06/2011. Available from: http://www.mhlw.go.jp/stf/shingi/2r9852000001hbq8-att/2r9852000001hd4o.pdf [Accessed on 7 April 2013]
- Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001275.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1 [Accessed on 7 April 2013]
- Rizzo M, Rizvi AA, Spinas GA, et al. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4-inhibitors. Expert Opin Investig Drugs 2009;18:1495-503
- Rizzo M, Nikolic D, Banach M, et al. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives. Clin Lipidol 2013;8:173-81
- Rizzo M, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. Curr Pharm Des 2011;17:3608-10